Gene Expression and Signal Transduction in Transformatio

我们的研究目标是了解细胞生长、分化和肿瘤转化的分子和遗传机制。我们研究了BALB/c小鼠浆细胞瘤、b细胞淋巴瘤和其他小鼠和人类实验肿瘤系统的癌基因、肿瘤抑制基因和信号转导蛋白。这些是有价值的实验模型，因为它们与人类多发性骨髓瘤、非霍奇金淋巴瘤和其他人类恶性肿瘤有许多共同的生物学和分子遗传学特征，需要了解这些肿瘤的机制，以便设计出更具体的治疗和预防措施。与人类伯基特淋巴瘤一样，BALB/c浆细胞瘤的特征是主要致癌基因c- myc的信使RNA和蛋白质的组成性表达。目前还不清楚，完全转化需要哪些额外的基因改变。一个可能是Myc表达改变的重要后果的机制是基因组不稳定，以染色体外和染色体内扩增的形式，以及随后对DNA合成和细胞增殖至关重要的几个基因的过表达，包括细胞周期蛋白D2。我们正在积极地研究有多少这样的基因可以被这种机制放大，以及是什么决定了它们的表达或缺乏。我们也在微阵列上使用基因表达谱来研究实验性浆细胞瘤中通过染色体易位激活c-myc的事件。

Our research objective is to understand the molecular and genetic mechanisms responsible for cell growth, differentiation and neoplastic transformation. We study the oncogenes, tumor-suppressor genes and signal-transducing proteins involved in BALB/c mouse plasmacytomas, B-cell lymphomas and other mouse and human experimental tumor systems. These are valuable experimental models, because they have many biological and molecular genetic features in common with human multiple myeloma, non-Hodgkin's lymphomas, and other human malignancies that are in need of mechanistic understanding in order to devise more specific therapy and preventive measures. BALB/c plasmacytomas, like human Burkitt lymphomas, are characterized by constitutive expression of messenger RNA and protein from the master oncogene, c-Myc. It is still not clear which additional genetic alterations are required for complete transformation. One mechanism that may be an important consequence of altered Myc expression is genomic instability, in the form of extra- and intra-chromosomal amplification, and the subsequent overexpression of several genes that are crucial for DNA synthesis and cell proliferation, including cyclin D2. We are actively engaged in learning how many such genes can be amplified by this mechanism and what determines their expression or lack thereof. We are also using gene expression profiling on microarrays to study the events that follow c-myc activation by chromosome translocation in experimental plasmacytomas. In the study of signal transduction, we are investigating protein kinase C (PKC), a multigene family of serine/threonine kinases that are important mediators of many forms of signal transduction. Using a variety of expression vectors, we have overexpressed many of the PKCs in fibroblasts, lymphocytic, myeloid and smooth muscle cell lines. This has made possible the identification of specific functions and intracellular targets for the individual PKC isoenzymes. We have been focusing on the delta and epsilon isoenzymes, which have opposite effects on cell proliferation. We have shown that most of the isoenzyme-specific determinants are located in the catalytic half (the carboxyl-terminal domain) of these PKCs by creating reciprocal chimeric cDNAs that encode molecules that are half PKC-delta and half PKC-epsilon. We are further dissecting the structure of the catalytic domain to determine which sub-domains determine PKC isoform- specific functions, focusing on the carboxy-terminal 50 amino acids, the "V5 domain." We are also studying the nature of PKC's involvement in apoptosis, in cytoskeleton-related changes in cell shape and motility, and in metastasis of these and other types of tumors, including human prostate cancer. We have shown that phorbol ester-activation of overexpressed PKC-delta disrupts the actin cytoskeleton in human and mouse lymphocytes, leading to the loss of membrane ruffling, a surface alteration needed for cell movement, and the loss of the typical elongated shape of these cells. We think that this effect is due to PKC-mediated changes in the phosphorylation of the adaptor molecule, paxillin. We have also shown that PKC-delta's role in apoptosis is not dependent on its kinase activity, and we are determining how many other isoform-specific function may be kinase-independent.